Global Prostate Cancer Antigen 3 Test Competitive Landscape Professional Research Report 2025
Research Summary
The Prostate Cancer Antigen 3 (PCA3) test is a diagnostic test used to help detect prostate cancer, particularly in men with elevated prostate-specific antigen (PSA) levels or abnormal digital rectal examination (DRE) results. Unlike the PSA test, which measures the levels of a protein produced by both normal and cancerous prostate cells, the PCA3 test specifically measures the levels of PCA3 RNA, a non-coding RNA molecule that is overexpressed in prostate cancer cells. The PCA3 test is typically performed on a urine sample collected after a digital rectal examination (DRE). Higher levels of PCA3 RNA in the urine sample may indicate the presence of prostate cancer. The PCA3 test is often used in conjunction with other diagnostic tests, such as PSA testing and prostate biopsy, to help assess the risk of prostate cancer and guide treatment decisions. While the PCA3 test can provide valuable information, it is not a standalone test for diagnosing prostate cancer and should be interpreted in conjunction with other clinical findings.
According to DIResearch's in-depth investigation and research, the global Prostate Cancer Antigen 3 Test market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Prostate Cancer Antigen 3 Test include MDxHealth, Myriad Genetics, Inc, Abbott, F. Hoffmann-La Roche Ltd, Siemens, OPKO Health, Inc, Genomic Health, BD, Agilent Technologies, Inc, Danaher etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Prostate Cancer Antigen 3 Test. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Prostate Cancer Antigen 3 Test market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Prostate Cancer Antigen 3 Test market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Prostate Cancer Antigen 3 Test industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Prostate Cancer Antigen 3 Test Include:
MDxHealth
Myriad Genetics, Inc
Abbott
F. Hoffmann-La Roche Ltd
Siemens
OPKO Health, Inc
Genomic Health
BD
Agilent Technologies, Inc
Danaher
Prostate Cancer Antigen 3 Test Product Segment Include:
RT-PCR
ELISA Test
Micro-neutralization Assays
Prostate Cancer Antigen 3 Test Product Application Include:
Hospital
Specialist Clinic
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Prostate Cancer Antigen 3 Test Industry PESTEL Analysis
Chapter 3: Global Prostate Cancer Antigen 3 Test Industry Porter’s Five Forces Analysis
Chapter 4: Global Prostate Cancer Antigen 3 Test Major Regional Market Size and Forecast Analysis
Chapter 5: Global Prostate Cancer Antigen 3 Test Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Prostate Cancer Antigen 3 Test Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Prostate Cancer Antigen 3 Test Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
- 1 Prostate Cancer Antigen 3 Test Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Prostate Cancer Antigen 3 Test Product by Type
- 1.2.1 RT-PCR
- 1.2.2 ELISA Test
- 1.2.3 Micro-neutralization Assays
- 1.3 Prostate Cancer Antigen 3 Test Product by Application
- 1.3.1 Hospital
- 1.3.2 Specialist Clinic
- 1.3.3 Other
- 1.4 Global Prostate Cancer Antigen 3 Test Market Size Analysis (2020-2032)
- 1.5 Prostate Cancer Antigen 3 Test Market Development Status and Trends
- 1.5.1 Prostate Cancer Antigen 3 Test Industry Development Status Analysis
- 1.5.2 Prostate Cancer Antigen 3 Test Industry Development Trends Analysis
- 2 Prostate Cancer Antigen 3 Test Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Prostate Cancer Antigen 3 Test Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Prostate Cancer Antigen 3 Test Market Analysis by Regions
- 4.1 Prostate Cancer Antigen 3 Test Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Prostate Cancer Antigen 3 Test Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Prostate Cancer Antigen 3 Test Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Prostate Cancer Antigen 3 Test Revenue Forecast by Region (2026-2032)
- 5 Global Prostate Cancer Antigen 3 Test Market Size by Type and Application
- 5.1 Global Prostate Cancer Antigen 3 Test Market Size by Type (2020-2032)
- 5.2 Global Prostate Cancer Antigen 3 Test Market Size by Application (2020-2032)
- 6 North America
- 6.1 North America Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Prostate Cancer Antigen 3 Test Market Size by Type
- 6.4 North America Prostate Cancer Antigen 3 Test Market Size by Application
- 6.5 North America Prostate Cancer Antigen 3 Test Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Prostate Cancer Antigen 3 Test Market Size by Type
- 7.4 Europe Prostate Cancer Antigen 3 Test Market Size by Application
- 7.5 Europe Prostate Cancer Antigen 3 Test Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Prostate Cancer Antigen 3 Test Market Size by Type
- 8.4 China Prostate Cancer Antigen 3 Test Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Prostate Cancer Antigen 3 Test Market Size by Type
- 9.4 APAC (excl. China) Prostate Cancer Antigen 3 Test Market Size by Application
- 9.5 APAC (excl. China) Prostate Cancer Antigen 3 Test Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Prostate Cancer Antigen 3 Test Market Size by Type
- 10.4 Latin America Prostate Cancer Antigen 3 Test Market Size by Application
- 10.5 Latin America Prostate Cancer Antigen 3 Test Market Size by Country
- 10.5.1 Mexico
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size by Type
- 11.4 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size by Application
- 11.5 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Prostate Cancer Antigen 3 Test Market Revenue by Key Manufacturers (2021-2025)
- 12.2 Prostate Cancer Antigen 3 Test Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Prostate Cancer Antigen 3 Test Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 MDxHealth
- 13.1.1 MDxHealth Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 MDxHealth Prostate Cancer Antigen 3 Test Product Portfolio
- 13.1.3 MDxHealth Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.2 Myriad Genetics, Inc
- 13.2.1 Myriad Genetics, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Myriad Genetics, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 13.2.3 Myriad Genetics, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.3 Abbott
- 13.3.1 Abbott Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Abbott Prostate Cancer Antigen 3 Test Product Portfolio
- 13.3.3 Abbott Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 F. Hoffmann-La Roche Ltd Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 F. Hoffmann-La Roche Ltd Prostate Cancer Antigen 3 Test Product Portfolio
- 13.4.3 F. Hoffmann-La Roche Ltd Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.5 Siemens
- 13.5.1 Siemens Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Siemens Prostate Cancer Antigen 3 Test Product Portfolio
- 13.5.3 Siemens Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.6 OPKO Health, Inc
- 13.6.1 OPKO Health, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 OPKO Health, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 13.6.3 OPKO Health, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.7 Genomic Health
- 13.7.1 Genomic Health Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Genomic Health Prostate Cancer Antigen 3 Test Product Portfolio
- 13.7.3 Genomic Health Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.8 BD
- 13.8.1 BD Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 BD Prostate Cancer Antigen 3 Test Product Portfolio
- 13.8.3 BD Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.9 Agilent Technologies, Inc
- 13.9.1 Agilent Technologies, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.9.2 Agilent Technologies, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 13.9.3 Agilent Technologies, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.10 Danaher
- 13.10.1 Danaher Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.10.2 Danaher Prostate Cancer Antigen 3 Test Product Portfolio
- 13.10.3 Danaher Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Prostate Cancer Antigen 3 Test Industry Chain Analysis
- 14.2 Prostate Cancer Antigen 3 Test Industry Raw Material and Suppliers Analysis
- 14.2.1 Prostate Cancer Antigen 3 Test Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Prostate Cancer Antigen 3 Test Typical Downstream Customers
- 14.4 Prostate Cancer Antigen 3 Test Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook